

# Nodulisporic Acid A Synthetic Studies. 1. Overall Strategy and Construction of a Western Hemisphere Subtarget


Amos B. Smith, III,\* Haruaki Ishiyama, Young Shin Cho, and Kazuyuki Ohmoto

Department of Chemistry, University of Pennsylvania,  
Philadelphia, Pennsylvania 19104

smithab@sas.upenn.edu

Received October 10, 2001


## ABSTRACT




In this, the first of two Letters, we outline our overall strategy for the construction of (+)-nodulisporic acid A (1), a representative member of a new class of indole diterpenes. In addition, we describe the efficient assembly of (-)-6, an advanced western hemisphere subtarget, comprising the ABC rings of (+)-nodulisporic acid A (1). The synthesis proceeded in 9% overall yield (longest linear sequence, 11 steps), exploiting a Shibasaki–Mori tandem transmetalation–cyclization to construct ring B.

(+)-Nodulisporic acid A (1, Figure 1), a novel insecticide recently isolated by Ondeyka and co-workers from the fermentation extract of the fungus *Nodulisporium* sp.<sup>1</sup> possesses unique architecture as deduced initially from spectroscopic evidence, including the Dunkel computerized 2D INADEQUATE protocol.<sup>2</sup> The relative stereochemistry was subsequently confirmed by single-crystal X-ray diffraction analysis of the *p*-bromobenzoate methyl ester derivative (2, Figure 1); the absolute stereochemistry was established by the advanced Mosher ester method.<sup>3</sup>

Nodulisporic acid A (1) proved to be a potent insecticide, discovered while screening the natural product extract against the larvae of the blowfly (*Lucilia sericata*; LC<sub>50</sub> of 0.3



1 (+)-Nodulisporic acid A R<sub>1</sub> = H, R<sub>2</sub> = H  
2 R<sub>1</sub> = CH<sub>3</sub>, R<sub>2</sub> = *p*-BrC<sub>6</sub>H<sub>4</sub>CO



3 (-)-Nodulisporic acid A<sub>1</sub> 4 (-)-Nodulisporic acid A<sub>2</sub>

Figure 1.

ppm).<sup>1</sup> Further study revealed that (+)-1 has an LC<sub>50</sub> of 0.5 ppm against *Aedes aegypti* (the larvae of the mosquito) and is more active than paraherquamide (LC<sub>50</sub> of 50 ppm in both

(1) Ondeyka, J. G.; Helms, G. L.; Hensens, O. D.; Goetz, M. A.; Zink, D. L.; Tsiouras, A.; Shoop, W. L.; Slayton, L.; Dombrowski, A. W.; Polishook, J. D.; Ostlind, D. A.; Tsou, N. N.; Ball, R. G.; Singh, S. B. *J. Am. Chem. Soc.* **1997**, *119*, 8809.

(2) (a) Dunkel, R.; Mayne, C. L.; Curtis, J.; Pugmire, R. J.; Grant, D. M. *J. Magn. Reson.* **1990**, *90*, 290. (b) Dunkel, R.; Mayne, C. L.; Pugmire, R. J.; Grant, D. M. *Anal. Chem.* **1992**, *64*, 3133. (c) Dunkel, R.; Mayne, C. L.; Foster, M. P.; Ireland, C. M.; Li, D.; Owen, N. L.; Pugmire, R. J.; Grant, D. M. *Anal. Chem.* **1992**, *64*, 3150.

(3) Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092.


assays) but less active than ivermectin, which displays an  $LC_{50}$  of 0.02 and 0.045 ppb, respectively.<sup>1</sup> Importantly, nodulisporic acid A was shown by the Merck group to possess potent oral activity in dogs for the control of fleas.<sup>4</sup> Subsequent research on the mechanism of action suggests that the insecticidal activity of (+)-**1** arises via modulation of the glutamate-gated chloride channels,<sup>5</sup> vital to insect neurotransmission. Interruption of the glutamate-gated chloride channels results in insect paralysis and death. Since glutamate-gated chloride channels are not found in mammals, nodulisporic acid A (**1**) holds considerable promise as a systemic insecticidal agent. Interestingly, despite the resemblance between nodulisporic acid A (**1**) and other complex indole tremorgens, such as janthitrem G<sup>6a</sup> and the shearinines,<sup>6b</sup> lolitremes,<sup>6c,d</sup> paspalitremes,<sup>6e</sup> and penitremes,<sup>6f</sup> (+)-**1** does not possess tremorgenic activity, presumably due to the lack of the C(9) axial hydroxyl group, as is known for the simple indole diterpenes paspline and paspalicine.<sup>7</sup> Currently, (+)-nodulisporic acid A (**1**) is under development by the Animal Health Division at Merck & Co.

More recently (1999), Hensens and co-workers at Merck disclosed the isolation and structure determination of two fermentation congeners, nodulisporic acid A<sub>1</sub> (**3**, Figure 1) and A<sub>2</sub> (**4**, Figure 1), which exhibit similar biological profiles;<sup>8</sup> nodulisporic acid A<sub>1</sub> (**3**) has an  $LD_{50}$  of 0.4–1.5 ppm against *Lucilia sericata*, similar to that of (+)-**1**, while nodulisporic acid A<sub>2</sub> (**4**) was slightly less active with an  $LD_{50}$  of 0.8–2.2 ppm.

Although nodulisporic acid A (**1**) resembles other indole diterpenes,<sup>6</sup> the unprecedented N1–C26 bridge with a readily epimerizable isoprenyl side chain, the A ring dihydropyran, and the cyclopentyl ring possessing a labile secondary benzylic hydroxyl conspire to make (+)-nodulisporic acid A (**1**) a most formidable synthetic target. Intrigued by the architectural complexity and the outstanding antiparasitic activity, we recently mounted an investigation with a view toward both total synthesis and analogue preparation. In this the first of two Letters,<sup>9</sup> we disclose our overall synthetic strategy in conjunction with an efficient assembly of tricyclic aniline (–)-**6**, complete with appropriate functionality for

further elaboration, that embodies the ABC western hemisphere rings of (+)-nodulisporic acid A (**1**). In the following Letter,<sup>9</sup> we describe an effective synthesis of the eastern hemisphere lactone **7**.

From the retrosynthetic perspective, initial scission between C(2'') and C(3'') and removal of the five-membered-ring isoprenyl moiety reveals indole **5** (Scheme 1), which,



in turn, is envisioned to arise via union of the western hemisphere **6** with the eastern hemisphere **7**, exploiting an indole ring synthetic protocol<sup>10</sup> that proved highly effective in our recent total synthesis of (–)-penitrem D.<sup>10d</sup> For **6**, the cyclopentane ring was expected to arise via a palladium-catalyzed tandem transmetalation–cyclization of **8**.<sup>11</sup> Asymmetric addition of SAMP hydrazone **9**<sup>12</sup> to aldehyde **10** in turn would provide, after removal of the chiral auxiliary and hydroxyl protection (TESCl), the requisite precursor for enol triflate **8**.

Assembly of western hemisphere (–)-**6** began with commercially available 3-amino-4-methylbenzyl alcohol **11**

(4) Shoop, W. L.; Gregory, L. M.; Zakson-Aiken, M.; Michael, B. F.; Haines, H. W.; Ondeyka, J. G.; Meinke, P. T.; Schmatz, D. M. *J. Parasitol.* **2001**, *87*, 419.

(5) (a) Smith, M. M.; Warren, V. A.; Thomas, B. S.; Brochu, R. M.; Ertel, E. A.; Rohrer, S.; Schaeffer, J.; Schmatz, D.; Petuch, B. R.; Tang, Y. S.; Meinke, P. T.; Kaczorowski, G. J.; Cohen, C. J. *Biochemistry* **2000**, *39*, 5543 (b) Kane, N. S.; Hirschberg, B.; Qian, S.; Hunt, D.; Thomas, B.; Brochu, R.; Ludmerer, S. W.; Zheng, Y.; Smith, M.; Arena, J. P.; Cohen, C. J.; Schmatz, D.; Warmke, J.; Cully, D. F. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 13949.

(6) (a) de Jesus, A. E.; Steyn, P. S.; van Heerden, F. R.; Vleggaar, R. J. *Chem. Soc., Perkin Trans. 1* **1984**, 697. (b) Belofsky, G. N.; Gloer, J. B.; Wicklow, D. T.; Dowd, P. F. *Tetrahedron* **1995**, *51*, 3959. (c) Gallagher, R. T.; Hawkes, A. D.; Steyn, P. S.; Vleggaar, R. J. *Chem. Soc., Chem. Commun.* **1984**, 614. (d) Ede, R. M.; Miles, C. O.; Meagher, L. P.; Munday, S. C.; Wilkins, A. L. *J. Agric. Food Chem.* **1994**, *42*, 231 and references therein. (e) Dorner, J. W.; Cole, R. J.; Cox, R. H.; Cunfer, B. M. *J. Agric. Food Chem.* **1984**, *32*, 1069 and references therein. (f) de Jesus, A. E.; Steyn, P. S.; van Heerden, F. R.; Vleggaar, R.; Wessels, P. L. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1857 and references therein.

(7) Dorner, J. W.; Cole, R. J.; Cox, R. H.; Cunfer, B. M. *J. Agric. Food Chem.* **1984**, *32*, 1069.

(8) Hensens, O. D.; Ondeyka, J. G.; Dombrowski, A. W.; Ostlind, D. A.; Zink, D. L. *Tetrahedron Lett.* **1999**, *40*, 5455.


(9) Smith, A. B., III; Cho, Y. S.; Ishiyama, H. *Org. Lett.* **2001**, *3*, 3971.

(10) (a) Smith, A. B., III; Visnick, M. *Tetrahedron Lett.* **1985**, *26*, 3757. (b) Smith, A. B., III; Visnick, M.; Haseltine, J. N.; Sprengeler, P. A. *Tetrahedron* **1986**, *42*, 2957. (c) Smith, A. B., III; Kanoh, N.; Minakawa, N.; Rainier, J. D.; Blase, F. R.; Hartz, R. A. *Org. Lett.* **1999**, *1*, 1263. (d) Smith, A. B., III; Kanoh, N.; Ishiyama, H.; Hartz, R. A. *J. Am. Chem. Soc.* **2000**, *122*, 11254.

(11) Mori, M.; Kaneta, N.; Shibasaki, M. *J. Org. Chem.* **1991**, *56*, 3486.

(12) (a) Enders, D.; Zamponi, A.; Raabe, G.; Runsink, J. *Synthesis* **1993**, 725. (b) Enders, D.; Whitehouse, D. L. *Synthesis* **1996**, 621.


### Scheme 2



(Scheme 2). Hydroxyl protection followed by regioselective iodination with benzyltrimethylammonium dichloriodate (BTMA·ICl<sub>2</sub>)<sup>13</sup> afforded amine **12**. Protection of the amino group as the phthalimide, hydrolytic removal of the TBS group, and oxidation of the resulting hydroxyl led to aldehyde **10** in 64% overall yield for the three steps.

Continuing with the synthesis, treatment of the Enders SAMP hydrazone (+)-**9**,<sup>12</sup> derived from known ketone **13**,<sup>14</sup> with *t*-BuLi at  $-78\text{ }^{\circ}\text{C}$  in THF, followed by addition of aldehyde **10** at  $-100\text{ }^{\circ}\text{C}$ , afforded a diastereomeric mixture of  $\beta$ -hydroxyhydrazones (11:2) in a combined yield of 84%; separation via flash chromatography provided (–)-**15** in 71% yield (Scheme 3). Ozonolysis then afforded  $\beta$ -hydroxyketone (–)-**16**.

### Scheme 3



The relative configurations of the newly generated stereocenters were assigned by conversion of (–)-**16** to the corresponding acetone (**17**) (catecholborane;<sup>15</sup> 2,2-dimethoxypropane, PPTS); NOESY spectral data revealed the 23*R*\*/24*S*\* relative configurations (Scheme 4).<sup>16</sup> The absolute configuration of (–)-**16** was then assigned by advanced Mosher ester analysis.<sup>3,17</sup> The pertinent data from the Kakisawa test of (–)-**16** are illustrated in Scheme 4.


(13) Kajigaeshi, S.; Kakinami, T.; Yamasaki, H.; Fujisaki, S.; Okamoto, T. *Bull. Chem. Soc. Jpn.* **1988**, *61*, 600.

(14) Magnus, P.; Mansley, T. E. *Tetrahedron Lett.* **1999**, *40*, 6909.

(15) Evans, D. A.; Chapman, K. T. *Tetrahedron Lett.* **1986**, *27*, 5939.


(16) Analysis of NOESY spectral data is shown in the Supporting Information.

### Scheme 4




Protection of the secondary hydroxyl in (–)-**16** (TESOTf, 2,6-lutidine), followed by formation of the enol triflate with the Comins reagent [*N*-(5-chloro-2-pyridyl)triflimide],<sup>18</sup> provided vinyl triflate (+)-**8** in 69% for the two steps (Scheme 5). The Shibasaki–Mori protocol<sup>11</sup> for tandem transmetalation–cyclization

### Scheme 5



–cyclization (i.e., conversion of the vinyl triflate to the vinylstannane and subsequent cyclization with aryl iodide)

(17) The minor product **i** was identified as below by Mosher ester analysis and NOESY experiment of its acetone derivative.




then furnished (–)-**18**. Unmasking the aniline moiety with hydrazine completed the synthesis of western hemisphere (–)-**6**.<sup>19</sup>

In summary, we have designed and executed an efficient synthesis of (–)-**6**, a western subtarget for (+)-nodulisporic acid A (**1**), by exploiting an asymmetric aldol reaction utilizing a SAMP hydrazone followed by a Shibasaki–Mori tandem transmetalation–cyclization. The synthesis proceeded in 11 steps and 9% overall yield. Importantly, the synthesis of (–)-**6** is highly competitive, compared to the recent synthesis by Magnus et al. of a racemic ABC model.<sup>14</sup>

(18) Comins, D. L.; Dehghani, A. *Tetrahedron Lett.* **1992**, *33*, 6299.

(19) We also observed as much as 27% of a reduced product, **ii**.



Studies to unite the western and eastern subtargets and complete the total synthesis of (+)-nodulisporic acid A (**1**) are currently ongoing in our laboratory.

**Acknowledgment.** Financial support was provided by the National Institutes of Health (National Institute of General Medical Sciences) through Grant GM-29028 and by the Merck Research Laboratories. We also thank Dr. G. Furst and Dr. R. K. Kohli, Directors of the University of Pennsylvania Spectroscopic Facilities, for assistance in obtaining NMR spectra and high-resolution mass spectra, respectively.

**Supporting Information Available:** Spectroscopic and analytical data for compounds **6**, **8**, **9**, **10**, **12**, **15**, **16**, **17**, and **18** and selected experimental procedures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0168871